Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PROC | P04070 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220050 | 1.00 | F10 (0.41) | F10F2METSPHK1SPHK2 | |
| SCHEMBL7457059 | 1.00 | F10 (0.41) | F10F2METSPHK1SPHK2 | |
| SCHEMBL7457063 | 0.87 | F10 (0.43) | F10F2PLGPROC | |
| SCHEMBL7220052 | 0.87 | F10 (0.43) | F10F2PLGPROC | |
| SCHEMBL23752546 | 0.82 | F10 (0.52) | F10F2PLAU | |
| SCHEMBL7213556 | 0.82 | F10 (0.42) | F10F2PLGPROCPLAU | |
| SCHEMBL6222403 | 0.82 | F10 (0.52) | F10F2PLAU | |
| SCHEMBL7448512 | 0.82 | F10 (0.42) | F10F2PLGPROCPLAU | |
| SCHEMBL6221084 | 0.81 | F10 (0.44) | F10F2METPLGPROC | |
| Hydrochloric Acid SCHEMBL6434810 | 0.81 | F10 (0.51) | F10F2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602864-B1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-05 | — | — | US | disclosed |
| EP-0944386-B1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA INC (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
| WO-2001039759-A2 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | STS, ARSA, F12 | F10 20/4885F2 11/4885MET 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.